SecBot SecBot
8-K ·Filed Jun 3, 2026

MDT

Medtronic plc
BULLISH
Impact 6/10
Horizonweeks Processed5mo ago SEC0001628280-26-040034
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong Q4 beat and above-consensus FY27 guidance (6.75-7.25% organic growth, $5.90-$6.00 EPS) should drive positive momentum. Watch for margin recovery as tariff and Blackstone headwinds ease. The 49th consecutive dividend increase reinforces capital return commitment.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$78.03
T+0 close · Jun 3, 2026 · via day close
Latest settled
+15.30%
T+60 · $89.97
Vs SPY
+13.07%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 3 $78.03entry
  2. T+1 · 6mo ago +4.97%α +4.57% · $81.91
  3. T+5 · 5mo ago +2.85%α +6.67% · $80.25
  4. T+20 · 5mo ago +1.50%α +2.63% · $79.20
  5. T+60 · 3mo ago +15.30%α +13.07% · $89.97

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Medtronic reported Q4 FY26 revenue of $9.807B (+9.9% YoY, +6.6% organic), beating the $9.61B consensus, and non-GAAP diluted EPS of $1.55, in line with the $1.55 consensus. The company guided FY27 organic revenue growth of 6.75%-7.25% and non-GAAP EPS of $5.90-$6.00, representing 6.7%-8.5% growth. Strong top-line performance and raised guidance are positive, but non-GAAP operating margin contracted 230bps YoY in Q4 and 130bps for FY26, with headwinds from tariffs and the MiniMed Blackstone payment.

Key Financial Metrics

EPS
$1.55
est $1.55 · 0.0%
Revenue
$9.8B
est $9.6B · +2.0% · +9.9% YoY
Rating
beat
Guidance
6.75%-7.25% organic growth
initiated
Free Cash Flow
$5.4B
Gross Margin
65.4%

Key Facts

  • Q4 FY26 revenue $9.807B, +9.9% reported, +6.6% organic, 90bps ahead of implied guidance
  • Q4 GAAP diluted EPS $0.96 (+17.1% YoY); non-GAAP diluted EPS $1.55 (-4.3% YoY)
  • FY26 revenue $36.364B (+8.4% reported, +5.8% organic); FY26 non-GAAP EPS $5.53 (+0.7% YoY)
  • FY27 guidance: organic revenue growth 6.75%-7.25%; non-GAAP EPS $5.90-$6.00 (6.7%-8.5% growth)
  • Dividend increased to $0.72/quarter ($2.88 annual), 49th consecutive annual increase
  • Cardiac Ablation Solutions revenue +78% globally, +124% US; Cardiovascular portfolio +10.1% organic
  • Q4 non-GAAP operating margin 25.5%, down 230bps YoY, impacted by 160bps from MiniMed Blackstone payment and 80bps from tariffs
  • FY26 free cash flow $5.426B, +4.6% YoY; returned $4.2B to shareholders

Financial Impact

Q4 revenue beat consensus by ~$197M (2.0%); FY27 EPS guidance midpoint $5.95 implies ~7.6% growth vs FY26 non-GAAP $5.53

revenueepsoperating marginfree cash flowdividend

Risk Factors

  • Non-GAAP operating margin contraction of 130bps in FY26 and 230bps in Q4 raises profitability concerns
  • Tariff headwinds of ~50bps on FY26 margins and potential escalation in FY27
  • Diabetes business separation structure remains undecided, creating execution uncertainty
  • FY26 non-GAAP EPS growth was only +0.7% despite 5.8% organic revenue growth, indicating cost pressures

Market Snapshot

Exchange
NYSE
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
57% bullish (37 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-040034
Document: mdt-20260603.htm0001628280-26-040034
Document: 0001628280-26-040034-index-headers.html0001628280-26-040034
Document: 0001628280-26-040034-index.html0001628280-26-040034
Document: 0001628280-26-040034.txt0001628280-26-040034
8-K Data (Synthetic)0001628280-26-040034

Track record

53 reports on MDT

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +15.29% at T+60 after the May 19, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $101.59 Now $102.88 +1.27% settles Feb 8
  3. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $98.88 Now $102.88 +4.05% settles Feb 1
  4. Oct 19, 202628d ago 8-K Neutral 4/10 Entry $94.63 Now $102.88 +8.72% settles Jan 15
  5. Oct 16, 20264w ago Insider Cluster Bearish 5/10 Entry $92.77 Now $102.88 −10.90% settles Jan 14
  6. Oct 16, 20264w ago Insider Cluster Bearish 5/10 Entry $92.77 Now $102.88 −10.90% settles Jan 14
  7. Oct 15, 20264w ago 144 Neutral 3/10 Entry $95.45 Now $102.88 +7.78% settles Jan 12
  8. Oct 14, 20264w ago SC TO-I/A Neutral 5/10 Entry $94.23 Now $102.88 +9.18% settles Jan 11
  9. Oct 14, 20264w ago 425 Neutral 5/10 Entry $94.23 Now $102.88 +9.18% settles Jan 11
  10. Oct 13, 20264w ago SC TO-I/A Neutral 5/10 Entry $93.01 Now $102.88 +10.61% settles Jan 8
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (11h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 3, 2026